Cargando…
Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable. We performed a systematic review of available pre-clinical data and human pharmacokine...
Autores principales: | Salam, Alex P., Duvignaud, Alexandre, Jaspard, Marie, Malvy, Denis, Carroll, Miles, Tarning, Joel, Olliaro, Piero L., Horby, Peter W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000057/ https://www.ncbi.nlm.nih.gov/pubmed/35353804 http://dx.doi.org/10.1371/journal.pntd.0010289 |
Ejemplares similares
-
Time to reconsider the role of ribavirin in Lassa fever
por: Salam, Alex Paddy, et al.
Publicado: (2021) -
Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies
por: Cheng, Hung-Yuan, et al.
Publicado: (2022) -
Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study
por: Duvignaud, Alexandre, et al.
Publicado: (2021) -
Ribavirin for Lassa Fever Postexposure Prophylaxis
por: Hadi, Christiane M., et al.
Publicado: (2010) -
A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever
por: Olayinka, Adebola Tolulope, et al.
Publicado: (2022)